Investigational Extended-Release Ralinepag for PAH Treatment Shows Favorable Results in Phase 1 Trials
Extended-release tablets of ralinepag, Arena Pharmaceuticals’ treatment candidate for pulmonary arterial hypertension (PAH), show a superior pharmacokinetic profile over both immediate-release ralinepeg capsules and approved immediate-release medication Uptravi (selexipag), according to two Phase 1 trials in healthy volunteers. Pharmacokinetics (PK) refer to how a drug is absorbed,…